Loading...
A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL‐1401O vs. EU‐trastuzumab and US‐trastuzumab
AIMS: Trastuzumab is a humanized monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2) oncoprotein and is an effective therapy for HER2‐overexpressing breast cancer. MYL‐1401O is a trastuzumab biosimilar. Here, we report results from a phase 1 study that investigated bio...
Na minha lista:
| Udgivet i: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6138509/ https://ncbi.nlm.nih.gov/pubmed/29926514 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13689 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|